<br><font size=2 face="sans-serif">Eric Cervera<br>
Public Relations Specialist<br>
Executive Summits Division. . . Where Business Does Business!<br>
Frost & Sullivan <br>
Office # 210-247-2446<br>
Fax # 210-348-1003<br>
http://www.summits.frost.com<br>
As a Growth Consulting organization, we enable our clients to meet their Growth Objectives by maximizing the results from their Growth Portfolio and identifying new Growth Opportunities..<br>
</font>
<br><font size=1 color=#800080 face="sans-serif">----- Forwarded by Eric Cervera/Mountain_View_CA/US/Frost & Sullivan on 09/23/02 11:27 AM -----</font>
<br>
<table width=100%>
<tr valign=top>
<td>
<td><font size=1 face="sans-serif"><b>"J.W. Bizzaro" <jeff@bioinformatics.org></b></font>
<br><font size=1 face="sans-serif">Sent by: jeff@dexter.geoserve.net</font>
<p><font size=1 face="sans-serif">09/23/02 11:26 AM</font>
<br>
<td><font size=1 face="Arial"> </font>
<br><font size=1 face="sans-serif"> To: Eric Cervera <ecervera@frost.com></font>
<br><font size=1 face="sans-serif"> cc: </font>
<br><font size=1 face="sans-serif"> Subject: Re: Help with an Executive Summit focused on</font></table>
<br>
<br>
<br><font size=2 face="Courier New">Hi Eric.<br>
<br>
You're welcome to send your message to our Bulletin Board:<br>
bbb@bioinformatics.org<br>
<br>
Cheers.<br>
Jeff<br>
<br>
Eric Cervera wrote:<br>
> <br>
> My name is Eric Cervera. I am the Public Relation<br>
> Specialist with Frost & Sullivan. I understand you are the<br>
> Newsletter and Website Content Editor for the<br>
> Bioinformatics.org. I was wondering I you could lend me a<br>
> hand on project I am working on. I am responsible for<br>
> evaluating and recruiting speaker and what we call Thought<br>
> Leader for our Executive Summits. I have and Executive<br>
> Summit coming up focused on Maximizing Outcomes of<br>
> Information Technology in Drug Discovery and Development<br>
> for which I am currently seeking nominations for the<br>
> position of Thought Leader .<br>
> <br>
> I was wondering if you would not mind sending the message<br>
> to you e-newsletter subscriber database. Below is the copy<br>
> for the message I am asking you to send. This is not a<br>
> sales call. There are no fees associated with being a<br>
> Thought Leader. The Thought Leader position is a<br>
> prestigious and important role. We will be recognizing<br>
> these Thought Leaders for the knowledge and experience.<br>
> <br>
> Please see the text below and let me know if this is doable.<br>
> ============================================================<br>
> =====================================<br>
> I am currently accepting nominations for the prestigious<br>
> role of Thought Leader at our high-caliber Executive Summit<br>
> focused on: Maximizing Outcomes of Information Technology<br>
> in Drug Discovery and Development.<br>
> <br>
> There are no presentations or speeches required. All I ask<br>
> it the Though Leader share his/her insight and perspective<br>
> in one of the topics listed below.<br>
> <br>
> Concurrent Thinktanks, November 5, 2002<br>
> __Thinktank 1: InSilico Drug Discovery<br>
> __Thinktank 2: Genomics<br>
> __Thinktank 3: Proteomics<br>
> <br>
> Concurrent Roundtables, November 6, 2002<br>
> __ Roundtable 1: Managing Focused Libraries<br>
> __ Roundtable 2: E-Clinical Integration<br>
> __ Roundtable 3: Personalized Medicine<br>
> <br>
> As a Thought Leader there are a number of exclusive<br>
> privileges you will enjoy:<br>
> Full Complimentary Thought Leader Pass for the Executive<br>
> Forum and General Session (Sunday-Wednesday $2095 value)<br>
> Your name, title and company in our program brochure and in<br>
> our program materials as a participating Thought Leader<br>
> Sunday's Executive Golf Tournament on us - we've got the<br>
> green fees!<br>
> Complimentary daily continental breakfast, lunch and<br>
> scheduled receptions and dinners<br>
> and more!<br>
> <br>
> The following is a list of confirmed Thought Leaders:<br>
> Francois Nader, MD, MBA, Senior Vice President Medical<br>
> Affairs, North America, Aventis Pharmaceutical<br>
> Kris Arora, PhD,Vice President, GRA Information Management,<br>
> Pharmacia<br>
> Sheryl Torr-Brown, PhD, Worldwide Head of Knowledge<br>
> Management and Scientific Development, Pfizer<br>
> Sangtae Kim, PhD, Vice President and Information Officer,<br>
> Lilly Research Laboratories<br>
> Mark Cockett, PhD, Executive Director, Applied Genomics,<br>
> Bristol-Myers Squibb Company<br>
> Charles Jaffe, MD, Ph.D, Director of Medical Informatics,<br>
> AstraZeneca Pharmaceuticals<br>
> Abdel Laoui, Head Chemoinformatics, Lead Generation<br>
> Informatics, Aventis<br>
> Nigel Beeley, PhD, Vice President and Chief Chemical<br>
> Officer- Arena Pharmaceuticals<br>
> Daniel Marshak, PhD, VP and Chief Technology Officer-<br>
> Cambrex<br>
> Joe Guiles, PhD, Director of High Throughput Chemistry,<br>
> Aventis Pharmaceuticals Inc.<br>
> Alan Wilson, PhD, Senior Director and Senior Fellow,<br>
> PreClinical Development, Pharmacia<br>
> Nathan Siemers, Associate Director of Bioinformatics,<br>
> Bristol-Myers Squibb Company<br>
> Bob Ladner, Sr. VP & Chief Science Officer, Dyax<br>
> Steven Gold, PhD, Director of Bioinformatics, CuraGen<br>
> Corporation<br>
> Thomas Rea, VP Bio-Pharmaceutical Development, Esperion<br>
> Therapeutics<br>
> Richard Labaurdiniere, PhD, Senior Vice President Research<br>
> and Development, Genome Therapeutics<br>
> Robert Davis, Executive VP of Drug Discovery, ACADIA<br>
> Pharmaceuticals<br>
> Lloyd Segal, President & CEO - Caprion Pharmaceuticals<br>
> Jurgen Bajorath Ph.D, Senior Director, Computer Aided Drug<br>
> Discovery, Albany Molecular Research<br>
> Jim Rizzi, Director of Computational Technology- Array<br>
> BioPharma<br>
> Bruce Keyt, PhD, Vice President Preclinical Development,<br>
> Abgenix Inc.<br>
> Robin Jackman, VP of Corporate Development, Sequenom<br>
> Terrence Chew, MD, SVP, Clinical and Regulatory, Peregrine<br>
> Pharmaceutical<br>
> David O'Reilly, VP of Corporate Development, Iconix<br>
> Pharmaceuticals<br>
> Sheila DeWitt, PhD, Vice President Drug Discovery, ArQule<br>
> John Saunders, PhD, Vice President of Chemistry, Neucrine<br>
> Biosciences, Inc.<br>
> <br>
> There are a few ground rules:<br>
> 1. You must be a Director or above.<br>
> 2. You must be from a Pharmaceutical or Biotechnology or<br>
> Biopharma company with sales in excess of $10 million/<br>
> year.<br>
> 4. Each nominee must go through a brief screening process.<br>
> 5. Rules subject to change<br>
> <br>
> For more information about this event go to<br>
> http://www.summits.frost.com<br>
> <br>
> Please call me at 210-355-4806 or email me at<br>
> ecervera@frost.com to nominate yourself or a colleague.<br>
> <br>
> Best,<br>
> Eric<br>
> <br>
> Eric Cervera<br>
> Public Relations Specialist<br>
> Executive Summits Division<br>
> Frost & Sullivan<br>
> Office # 210-247-2446<br>
> Fax # 210-348-1003<br>
> http://www.summits.frost.com<br>
<br>
-- <br>
J.W. Bizzaro jeff@bioinformatics.org<br>
Director, Bioinformatics.Org http://bioinformatics.org/~jeff<br>
"As we enjoy great advantages from the inventions of others, we<br>
should be glad of an opportunity to serve others by any invention<br>
of ours; and this we should do freely and generously."<br>
-- Benjamin Franklin<br>
--<br>
</font>
<br>
<br><font size=2 face="Arial">===============================================================</font>
<br><font size=1 face="Arial"><b>Frost & Sullivan</b></font>
<br><font size=1 face="Arial"><b>http://www.frost.com</b></font>
<br>
<br><font size=1 face="Arial">This email, its content and any files transmitted with it are intended solely for the addressee(s) and may be </font>
<br><font size=1 face="Arial">legally privileged and/or confidential. If you are not the intended recipient please delete and contact the </font>
<br><font size=1 face="Arial">sender by return. </font>
<br><font size=1 face="Arial"><br>
Messages sent via this medium may be subject to delays, non-delivery and unauthorized alteration. This </font>
<br><font size=1 face="Arial">email has been prepared using information believed by the author to be reliable and accurate, but Frost & </font>
<br><font size=1 face="Arial">Sullivan makes no warranty as to accuracy or completeness. In particular, Frost & Sullivan does not </font>
<br><font size=1 face="Arial">accept responsibility for changes made to this email after it was sent. Any opinions or recommendations </font>
<br><font size=1 face="Arial">expressed herein are solely those of the author. They may be subject to change without notice.</font>
<br>